Compare Moderna, Inc. (MRNA) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Otis Worldwide Corp — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Otis Worldwide Corp trades at $65.95 (market cap $25.17B). The key difference: Moderna, Inc. is far larger — about 3.1× Otis Worldwide Corp's market cap, and Otis Worldwide Corp pays a 2.66% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Otis Worldwide Corp for 66 Days on average.
| MRNA | OTIS | |
|---|---|---|
Market Cap | $78.65B | $25.17B |
Volume | 37,373,437 | 4,542,442 |
Sector | Health | Industrials |
52-Week High | $203.46 | $93.62 |
52-Week Low | $22.36 | $64.05 |
Typical Hold Time | 59 Days | 66 Days |
Enterprise Value | $74.80B | $33.20B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Otis Worldwide trades at $66.11, near its 52-week low, with a bearish technical signal and recent earnings misses in Q4 2025, Q1 2026, and Q2 2026. The company maintains stable revenue around $14.4B in 2025 but faces margin pressure, with net income margin at 10.17%. Analyst consensus is split between Buy and Hold, with a price target of $87.00, indicating potential upside. Recent news highlights CEO succession plans and challenges in China demand.
The outlook for Otis hinges on service margin recovery and China market stabilization. Investment opportunities include its dominant market position and durable cash flow from service contracts, but risks involve persistent cost pressures, high debt levels, and weak equipment demand. Wall Street remains cautiously optimistic given the valuation discount to targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
